Today, clinical researchers are using automated, end-to-end solutions to make the most of limited liquid biopsy samples. To enable this work, leaders in the field are partnering with us to design next-generation sequencing (NGS) assays that target critical questions in cancer research and tumor biology.<\/p>\n
Professor Jos\u00e9 Luis Costa<\/a><\/strong>, PhD,\u00a0i3S\/IPATIMUP<\/span>, is leading efforts to use cell-free DNA (cfDNA) to detect rare mutations in lung cancer research blood samples. After his workshop at the Association of Molecular Pathology, we talked with him about the liquid biopsy applications<\/a><\/u>.<\/p>\n